The scientists who undertook the study in the US suggest this could lead to development of new drug treatments in Alzheimer's disease.

The study found that a reduction in a specific signalling cascade, known as Insulin-Insulin Growth Factor (IGF) signalling might enhance activity in brain mechanisms that could protect against Alzheimer's. The mice, genetically modified to develop Alzheimer's disease, had less inflammation in the brain when this signalling was reduced.

Susanne Sorensen, Head of Research, Alzheimer's Society says,

'This interesting study identifies new avenues for drug development that target this process associated with ageing. Drugs take years to develop and new treatments based on this discovery may be a long way from hitting pharmacy shelves. Dementia research is desperately underfunded and without investment new treatments will not become available. One million people will develop dementia in the next 10 years. We must act now.'

Dr Susanne Sorensen
Head of Research
Alzheimer's Society